Today: 9 June 2026
Accenture stock drops 3% to start 2026 — here’s what could move ACN next
4 January 2026
1 min read

Accenture stock drops 3% to start 2026 — here’s what could move ACN next

NEW YORK, Jan 4, 2026, 14:58 ET — Market closed

  • Accenture shares fell 3.1% on Friday to $259.95, extending a three-session losing streak.
  • The stock is about 35% below its 52-week high of $398.35 hit on Feb. 5.
  • Investors are watching Jan. 9 U.S. jobs data and Accenture’s March 19 earnings call for the next direction cue.

Accenture plc (ACN) shares ended Friday down 3.1% at $259.95, their third straight session of losses.

The decline left the IT consulting firm lagging a broader market that finished higher on the first trading day of 2026, helped by gains in chipmakers.

Why it matters now: Accenture heads into the first full week of the year with its stock about 35% below its 52-week high of $398.35, leaving the shares more sensitive to shifts in risk appetite.

Macro catalysts arrive before company ones. The U.S. government is scheduled to publish the December employment report on Jan. 9 and the consumer price index on Jan. 13, data that investors use to gauge the interest-rate outlook.

Accenture traded between $258.07 and $271.92 on Friday and finished near the session low — levels traders often use as near-term support and resistance.

Trading volume was about 4.9 million shares, above its 50-day average of 3.8 million, MarketWatch data showed.

Accenture also fell more than some peers in the session, with IBM, ADP and Cognizant ending lower but by smaller amounts, according to MarketWatch.

In the broader market, investors have been quick to trade around volatility. Joe Mazzola, head of trading and derivatives strategy at Charles Schwab, described the mood as “buy the dip, sell the rip,” in comments to Reuters. Reuters

For Accenture, the underlying debate remains how durable demand is for AI-related work versus softer pockets elsewhere. In its Dec. 18 results, the company posted first-quarter revenue of $18.74 billion and said new bookings totaled about $21 billion; bookings are the value of contracts signed and are watched as a signal of future revenue.

But Accenture also forecast second-quarter revenue of $17.35 billion to $18.0 billion, with the midpoint below analysts’ expectation of $17.78 billion, according to LSEG data cited by Reuters, and it flagged uneven demand from public sector and government clients amid efforts to curb spending.

A key risk is that a broader pullback in discretionary consulting spend — or a deeper slowdown in government-related work — hits new bookings and keeps pressure on the shares as 2026 begins.

Looking ahead, Accenture’s next major company event is its second-quarter fiscal 2026 earnings call on March 19.

Stock Market Today

  • Nuvalent Shares Surge Near $124 Following GSK's $10.6 Billion Buyout Offer
    June 9, 2026, 10:35 AM EDT. Nuvalent's stock jumped 38.9% to $122.93 after GSK announced a $10.6 billion cash acquisition at $124 per share, reflecting a 40% premium to the last close. The deal highlights GSK's strategic move to expand its oncology portfolio beyond its current 6% share of sales, aiming to capitalize on Nuvalent's two lung cancer drugs pending FDA decisions this year. The tender offer needs the approval of at least half of Nuvalent's Class A shares and U.S. antitrust clearance. Early analyst reactions included target price adjustments but echoed caution over valuation. Nuvalent's pipeline products could face competition from existing ALK-targeted therapies by Pfizer and Roche.

Latest articles

Autozi Shares Jump 400%, Filing Flags Risks for AZI

Autozi Shares Jump 400%, Filing Flags Risks for AZI

9 June 2026
Autozi Internet Technology shares soared over 400% to $5.69 in early Nasdaq trading after a 10-for-1 share consolidation slashed its share count to about 4.49 million, but the surge contrasts with a 63.1% revenue drop, 82.5% plunge in gross profit, and widened net loss, with the company warning of “substantial doubt” about its ability to continue as a going concern.
Redwire Shares Slip After $500 Million Stock Offering Filed

Redwire Shares Slip After $500 Million Stock Offering Filed

9 June 2026
Redwire Corp shares plunged 6.5% to $17.37 after launching a $500 million at-the-market stock program, raising dilution risks for investors as the company seeks flexible funding despite recent record backlog and strong revenue growth; the drop contrasted with gains at other space stocks, highlighting investor concern over potential share issuance.
Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

9 June 2026
Nuvalent shares soared 38.9% to $122.93, just below GSK’s $124-a-share cash offer after the $10.6 billion buyout was announced, as investors bet on the deal closing with Nuvalent’s two lead lung-cancer drugs already under FDA review and a 40% premium to the last closing price driving the morning’s merger-arb trade.
Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
Tesco issues urgent “do not eat” recall for three pate lines after date-label error
Previous Story

Tesco issues urgent “do not eat” recall for three pate lines after date-label error

Oracle stock: 3 catalysts that could move ORCL when markets reopen
Next Story

Oracle stock: 3 catalysts that could move ORCL when markets reopen

Go toTop